Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

The following inclusion criteria were applied: * all other treatment options had been exhausted * patient was ineligible for any ongoing trials or was geographically inaccessible to trials including a trial with derazantinib * there was a reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product * patient was willing and able to provide written informed consent * if applicable, regulatory approval by the appropriate jurisdiction was obtained